Aquestive Therapeutics Inc. (AQST) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Aquestive Therapeutics Inc. (NASDAQ: AQST) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $3.89 (-3.71% 1D, market cap $507.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AQST ranks #1005 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AQST carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of 58.3%, and ROIC of -35.0%. By comparison, OCS (Oculis Holding AG) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $507.5M) and PHAT (Phathom Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $503.2M). Among the 5-stock peer group, AQST leads on earnings multiple (N/A) while AQST leads on capital efficiency (-35.0% ROIC).
Per AQST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001398733), Aquestive Therapeutics Inc. generated $44.5M in revenue (-22.6% YoY), -$83.8M in net income, and -$53.0M in free cash flow against $160.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 58.3% Gross Margin
20D Institutional Volume Accumulation (±11.6% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While AQST currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.65) and Max Pain ($4.08) forces dealer call-delta covering toward $7.21.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Aquestive Therapeutics Inc. (AQST) dropped -3.71% to $3.89, trading at 24% of its 52-week range ($2.93 – $6.87). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.
Schubert Jonckheer & Kolbe report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.
WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' liv
FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027Ex-U.S. strategy remains on track with Canadian NDS planned f
FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027Ex-U.S. strategy remains on track with Canadian NDS planned
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -22.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AQST today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AQST. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Aquestive Therapeutics Inc. (AQST) ranks #1005 by composite RQD confidence (18/100, grade E) and #449 by equity capitalization ($507.1M). Within this direct 5-issuer industry benchmark cohort, AQST leads on earnings valuation at N/A trailing P/E, while AQST leads on capital efficiency and profitability with -35.0% ROIC and 58.3% gross margin. OCS currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with AQST at 18/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AQST
ACTIVE
Aquestive Therapeutics Inc. | E | 18/100 | — | 58.3% | -35.0% | -3.71% | $507.1M | Benchmark Subject |
| OCS Oculis Holding AG | D | 47/100 | — | — | — | +0.24% | $507.5M | /ocs-vs-aqst → |
| PHAT Phathom Pharmaceuticals Inc. | E | 34/100 | — | 87.1% | -35.0% | -7.72% | $503.2M | /phat-vs-aqst → |
| INDP Indaptus Therapeutics Inc. | D | 44/100 | — | — | -35.0% | -7.48% | $513.0M | /indp-vs-aqst → |
| DMAC DiaMedica Therapeutics Inc. | D | 44/100 | — | — | -35.0% | -2.84% | $513.4M | /dmac-vs-aqst → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aquestive Therapeutics Inc. (AQST) reported GAAP revenue of $44.5M (-22.6% vs. FY2024 revenue of $57.6M , and -11.9% cumulative change since FY2023) , GAAP net income of -$83.8M, operating cash flow of -$52.4M, and free cash flow of -$53.0M (-47.5% YoY). On the balance sheet, AQST closed FY2025 with $160.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $44.5M | -$83.8M | -$52.4M | -$53.0M | $160.4M | — |
| FY2024 (FY) | 2024-12-31 | $57.6M | -$44.1M | -$35.8M | -$35.9M | $101.4M | — |
| FY2023 (FY) | 2023-12-31 | $50.6M | -$7.9M | -$6.4M | -$6.4M | — | — |
As of 2026-11-02, Aquestive Therapeutics Inc. (NASDAQ: AQST) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $3.89 (-3.71% 1D, market cap $507.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AQST ranks #1005 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AQST carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of 58.3%, and ROIC of -35.0%. By comparison, OCS (Oculis Holding AG) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $507.5M) and PHAT (Phathom Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $503.2M). Among the 5-stock peer group, AQST leads on earnings multiple (N/A) while AQST leads on capital efficiency (-35.0% ROIC).
Per AQST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001398733), Aquestive Therapeutics Inc. generated $44.5M in revenue (-22.6% YoY), -$83.8M in net income, and -$53.0M in free cash flow against $160.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
AQST last traded at $3.89 (-3.71% on volume of 2,420,007 shares), positioning the stock -16.34% below its 50-day simple moving average ($4.65) and -7.60% below its 200-day simple moving average ($4.21). Across its 52-week range of $2.93 to $6.87, AQST sits at the 24.4% percentile with a 14-day RSI of 42.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.6% ($3.44 to $4.34).
Why AQST Stock dropped -3.71% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, AQST scores 18 out of 100 and receives a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." Each pillar is scored out of 20:
Taken together, the rating points to a company with negative operating economics, a strained balance-sheet signal, and weak ownership and insider signals. The upside case an investor would need to underwrite is a return to cash generation, which the reported financials have not yet demonstrated. Valuation tradeoffs are difficult to assess because the P/E and EV/EBITDA measures are not available in the source data, so the rating's forensic and cash-flow pillars carry most of the analytical weight.
Aquestive Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $0.5B. The source data does not detail its specific products, customers, or revenue model, so how the company makes money cannot be described beyond its reported revenue figures in the Financial Trend section.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $44.5M | $-71.1M | $-83.8M | N/A | $-53.0M | $121.2M | N/A |
| FY 2024 | $57.6M | $-30.8M | $-44.1M | N/A | $-35.9M | $71.5M | N/A |
| FY 2023 | $50.6M | $-15.1M | $-7.9M | N/A | $-6.4M | N/A | N/A |
Per the SEC financials, revenue fell from $57.6M in FY 2024 to $44.5M in FY 2025, while net losses widened from $-44.1M to $-83.8M. Per the market data, the gross margin is 58.3%, but the operating and net margins are both -60%, and ROIC is -35%. The Altman Z-Score of 0.2 and Piotroski F-Score of 3/9 (per the Roarable RQD rating) indicate a weak financial position, and Debt/Equity is 0.5. Reported cash of $121.2M in FY 2025 is above the FY 2024 level of $71.5M, though the FCF figures remain negative in every reported year.
Per the recent news feed, the most prominent items are:
The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals, so no butterfly-derived signal is available.
Real-time company headlines, analyst actions, and sector developments for Aquestive Therapeutics Inc. (AQST) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.
Schubert Jonckheer & Kolbe report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Aquestive Therapeutics Inc. (AQST) market action, institutional positioning, and fundamental catalysts.
WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' liv
Welcome to the AQST (Aquestive Therapeutics Inc.) Roar Pit. Current RQD Composite is 18/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on AQST, but look at what you are paying: current EV/EBITDA multiples with 58.3% gross margins. Unless Aquestive Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on AQST, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $4.04 (52-wk range $2.93 - $6.87), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).